PYC Therapeutics (ASX:PYC) Shares Outstanding (EOP): 597.26 Mil (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
35 GF Score
Price A$1.54
! 2 Warning Signs
View Full Analysis

What is PYC Therapeutics Shares Outstanding (EOP)?

PYC Therapeutics ASX:PYC 35 Shares Outstanding (EOP) is 597.26 Mil as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. PYC Therapeutics's shares outstanding for the quarter that ended in Dec. 2025 was 597.26 Mil.

PYC Therapeutics's quarterly shares outstanding stayed the same from Jun. 2025 (597.26 Mil) to Dec. 2025 (597.26 Mil).

PYC Therapeutics's annual shares outstanding increased from Jun. 2024 (480.42 Mil) to Jun. 2025 (597.26 Mil). It means PYC Therapeutics issued new shares from Jun. 2024 to Jun. 2025 .


PYC Therapeutics  (ASX:PYC) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


PYC Therapeutics Shares Outstanding (EOP) Related Terms


PYC Therapeutics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics Shares Outstanding (EOP) Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 331.41 331.41 355.95 480.42 597.26

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 388.92 480.42 480.42 597.26 597.26

ASX:PYC vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, PYC Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PYC Therapeutics Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Shares Outstanding (EOP) falls into.


ASX:PYC
35GF Score
PYC Therapeutics Ltd ASX:PYC
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 597.26 Mil mean?
PYC Therapeutics (ASX:PYC) has a Shares Outstanding (EOP) of 597.26 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' Shares Outstanding (EOP) too high?
PYC Therapeutics' current Shares Outstanding (EOP) is 597.26 Mil. Overall, PYC Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' Shares Outstanding (EOP) compare to VRTX and REGN?
PYC Therapeutics' Shares Outstanding (EOP) of 597.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current Shares Outstanding (EOP) is 597.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current Shares Outstanding (EOP) of 597.26 Mil. The current Shares Outstanding (EOP) is 597.26 Mil. PYC Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current Shares Outstanding (EOP) is 597.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:PYC

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price